Sector News

Industry experts weigh in on slew of bills aimed at drug price transparency at hearing

May 22, 2019
Life sciences

Experts from across the healthcare system weighed in on several House bills aimed at increasing transparency in the pharmaceutical supply chain at a hearing Tuesday.

Seven pieces of legislation, all of which are bipartisan, were on the slate for discussion at the House Energy and Commerce Committee Subcommittee on Health hearing. Amid the political fervor over rising drug prices, shining a light on how prices are determined has been a key focus for policymakers.

However, some in the industry warn that there may be too much of a good thing and that making all data public could undermine the goal of bringing down costs. Kristin Bass, chief policy and external affairs officer for the Pharmaceutical Care Management Association (PCMA), said the group backs releasing data on rebates and negotiations in “aggregate.”

But the pharmacy benefit management (PBM) trade group fears that fully public data would prevent effective negotiation with drug companies, Bass said.

“We have issues around public reporting when it would allow for tacit collusion” among drugmakers, she said.

Mark Miller, executive vice president of healthcare at Arnold Ventures, said greater transparency could “compel the issue forward.” However, on its own, transparency isn’t going to revolutionarily change how drugs are priced, he said.

None of the bills in question for Tuesday’s hearing would have forced PBMs to publicly disclose individual rebates negotiated for specific drugs, though one would make them release the data in aggregate.

Bass said that PCMA would recommend policymakers release such data by class for those with at least three drugs. It also suggests a lag time of several years for the data to be published to allow PBMs to adjust to existing contracts.

The ongoing debate on whether to eliminate rebates negotiated by PBMs entirely from the system was also on the slate at the hearing. Legislators pushed back on the fact that some PBMs will put drugs with higher list prices on the formulary instead of lower-cost alternatives.

Bass said insurers select drugs with the lowest net price—the price after rebates and other discounts have been factored in—and often that’s the drug with the higher list price.

Eliminating rebates, she said, would not put pressure on drug companies to lower list prices on their own, a point that others in the insurance industry have also noted. Studies have also suggested that the Trump administration’s plan to do so in Part D would increase premiums and taxpayer spending.

That said, the industry should indeed be looking at the concerns raised by rebates’ critics, she said.

“We do think there is a conversation to be around the price concessions,” Bass said.

By Paige Minemyer

Source: Fierce Healthcare

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.